

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-7. (Canceled)

8. (Currently Amended) A method of promoting wound healing comprising applying a pharmaceutical composition comprising a homogeneous, total keratinocyte lysate non-viable cell lysate and 0.001-1 w/v% xanthan gum as an at least one antiflocculant and/or antisedimentation agent(s), wherein antiflocculant and/or antisedimentation agent is xanthan gum to an area of skin in need of said promoting.

Claims 9-14. (Canceled)

15. (Previously Presented) The method of claim 8 wherein said wound is at least one of a wound and a skin ulcer.

16. (Previously Presented) The method of claim 8 wherein said composition is in the form of a dry powder, a freeze-dried form, a suspension or a solution.

17. (Previously Presented) The method of claim 8 wherein said composition is in the form of a gel, a cream, an ointment or a biocompatible matrix.

18. (Currently Amended) The method of claim 8 wherein said composition further comprises antiflocculant and /or antisedimentation agent is combination of xanthan gum and maltodextrin.

19. (Previously Presented) The method of claim 8 wherein said composition further comprising a buffering agent.

Claim 20. (Canceled)

21. (Previously Presented) The method of claim 8 wherein said composition further comprises a pharmaceutically acceptable carrier/excipient/vehicle.

22. (Currently Amended) The method of claim 8 wherein said composition further comprises a non-viable cell lysate and a pharmaceutically acceptable vehicle.

23. (Previously Presented) The method of claim 21 wherein said pharmaceutically acceptable vehicle is a dry powder, a suspension or a solution.

24. (Previously Presented) The method of claim 21 wherein said pharmaceutically acceptable vehicle is a gel, cream, ointment or a biocompatible matrix

25. (new) A pharmaceutical composition comprising a homogeneous, total keratinocyte lysate and 0.001-1 w/v% xanthan gum as an antiflocculant and/or antisedimentation.

26. (new) The composition of claim 25, said composition being in the form of a dry powder, a freeze-dried form, a suspension or a solution.

27. (new) The composition of claim 25, said composition being in the form of a gel, a cream, an ointment or a biocompatible matrix.

28. (new) The composition of claim 25, further comprises maltodextrin.

29. (new) The composition of claim 25, further comprising a buffering agent.

30. (new) The composition of claim 25, further comprises a pharmaceutically acceptable carrier/excipient/vehicle.

31. (new) The composition of claim 25, further comprising a pharmaceutically acceptable vehicle.

32. (new) The composition of claim 30, said composition being in the form of a dry powder, a suspension or a solution.

33. (new) The composition of claim 30, wherein said composition is in the form of a gel, a cream, an ointment or a biocompatible matrix.